Loading…
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $74M | $-559M | $-645M | $-380M | -57.0% | 27.0% | - |
| 2024 | $58M | $-427M | $-464M | $-376M | -44.8% | 33.3% | - |
| 2023 | $44M | $-308M | $-328M | $-300M | -70.8% | 10.6% | - |
| 2022 | $40M | $-228M | $-239M | $-121M | -49.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 39.68 | 43.88 | 58.49 | 74.26 |
| Cost Of Revenue | 48.27 | 42.59 | 45.24 | 70.95 |
| Gross Profit | -8.59 | 1.29 | 13.25 | 3.30 |
| Operating Expense | 237.13 | 351.35 | 492.25 | 651.43 |
| Operating Income | -245.73 | -350.06 | -479 | -648.13 |
| EBITDA | -227.66 | -307.63 | -426.72 | -559.38 |
| EBIT | -239.42 | -332.03 | -463.22 | -643.09 |
| Pretax Income | -239.48 | -332.13 | -464.79 | -644.89 |
| Tax Provision | 0 | -4.06 | -1.13 | -0.14 |
| Net Income | -239.48 | -328.07 | -463.66 | -644.76 |
| Net Income Common Stockholders | -239.48 | -328.07 | -463.66 | -644.76 |
| Total Expenses | 285.41 | 393.94 | 537.49 | 722.39 |
| Interest Expense | 0.06 | 0.10 | 1.57 | 1.81 |
| Interest Income | 6.25 | 19.12 | 15.76 | 22.79 |
| Research And Development | 155.70 | 241.23 | 314.42 | 475.27 |
| Selling General And Administration | 81.60 | 110.82 | 178.18 | 176.59 |
| Normalized EBITDA | -227.66 | -307.63 | -426.72 | -559.38 |
| Normalized Income | -239.48 | -328.07 | -463.66 | -644.76 |
| Basic EPS | -1.36 | -1.58 | -1.69 | -1.44 |
| Diluted EPS | -1.36 | -1.58 | -1.69 | -1.44 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0.01 | 0 | 0 |
| Total Unusual Items | 0 | 0 | 0 | 0 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -239.48 | -328.07 | -463.66 | -644.76 |
| Reconciled Depreciation | 11.76 | 24.40 | 36.49 | 83.70 |
| Reconciled Cost Of Revenue | 48.27 | 42.59 | 45.24 | 70.95 |
| Net Interest Income | 6.20 | 19.02 | 14.19 | 20.98 |
| Net Income From Continuing And Discontinued Operation | -239.48 | -328.07 | -463.66 | -644.76 |
| Total Operating Income As Reported | -245.73 | -350.06 | -479 | -648.13 |
| Diluted Average Shares | 175.54 | 207.85 | 274.21 | 447.45 |
| Basic Average Shares | 175.54 | 207.85 | 274.21 | 447.45 |
| Diluted NI Availto Com Stockholders | -239.48 | -328.07 | -463.66 | -644.76 |
| Net Income Including Noncontrolling Interests | -239.48 | -328.07 | -463.66 | -644.76 |
| Net Income Continuous Operations | -239.48 | -328.07 | -463.66 | -644.76 |
| Other Income Expense | 0.05 | -1.09 | 0.03 | -17.74 |
| Other Non Operating Income Expenses | 0.05 | -1.09 | 0.03 | -17.74 |
| Special Income Charges | 0 | 0 | 0 | 0 |
| Other Special Charges | 0 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | 6.20 | 19.02 | 14.19 | 20.98 |
| Interest Expense Non Operating | 0.06 | 0.10 | 1.57 | 1.81 |
| Interest Income Non Operating | 6.25 | 19.12 | 15.76 | 22.79 |
| Other Operating Expenses | -0.16 | -0.70 | -0.35 | -0.42 |
| General And Administrative Expense | 81.60 | 110.82 | 178.18 | 176.59 |
| Other Gand A | 81.60 | 110.82 | 178.18 | 176.59 |
| Operating Revenue | 39.68 | 43.88 | 58.49 | 74.26 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Recursion Pharmaceuticals, Inc.this co. | RXRX | $1.7B | - | 1.54 | -57.0% | -1.91 |
| AnaptysBio, Inc. | ANAB | $1.8B | - | 46.94 | -35.6% | 36.55 |
| Taysha Gene Therapies, Inc. | TSHA | $1.8B | - | 7.24 | -44.1% | -14.19 |
| Sonida Senior Living, Inc. | SNDA | $1.8B | - | -37500.00 | -125.8% | 57.41 |
| Harmony Biosciences Holdings, Inc. | HRMY |
| $1.8B |
| 11.23 |
| 2.05 |
| 18.2% |
| 4.68 |
| Palvella Therapeutics, Inc. | PVLA | $1.8B | - | 54.18 | -149.1% | - |
| Amylyx Pharmaceuticals, Inc. | AMLX | $1.7B | - | 5.62 | -47.4% | -9.25 |
| Nurix Therapeutics, Inc. | NRIX | $1.7B | - | 3.57 | -49.1% | -4.02 |
| Sionna Therapeutics, Inc. | SION | $1.7B | - | 5.46 | -24.5% | -16.50 |
| Peer Median | - | 11.23 | 5.54 | -45.8% | -4.02 | |